Antibodies
4 March 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)3 March 2008
BioWa Announces Expansion of License Agreement With Genetech for BioWa’s POTELLIGENT(R) Technology29 February 2008
Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancer27 February 2008
MorphoSys and Sigma-Aldrich Enter into a Collaboration and Licensing Agreement for Recombinant Research Antibodies27 February 2008
FDA Approves Regeneron’s ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)25 February 2008
ESBATech’s Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery Via Eye Drops22 February 2008
Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis21 February 2008
MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies20 February 2008
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss19 February 2008
InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast Cancer18 February 2008
Takeda Discontinues Development of Matuzumab18 February 2008
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties13 February 2008
Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint13 February 2008
YM BioSciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Caincer13 February 2008
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas12 February 2008
Sanofi-aventis enters into Antibody Agreements with Dyaxand “Phage Display Technology”12 February 2008
MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program12 February 2008
Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.11 February 2008
FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCANNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports